1.18
price down icon2.48%   -0.03
after-market After Hours: 1.22 0.04 +3.39%
loading
Pds Biotechnology Corporation stock is traded at $1.18, with a volume of 238.59K. It is down -2.48% in the last 24 hours and down -21.85% over the past month. PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.21
Open:
$1.22
24h Volume:
238.59K
Relative Volume:
0.48
Market Cap:
$53.94M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-1.0085
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
+2.61%
1M Performance:
-21.85%
6M Performance:
-23.87%
1Y Performance:
-70.05%
1-Day Range:
Value
$1.15
$1.2296
1-Week Range:
Value
$1.12
$1.2691
52-Week Range:
Value
$0.8505
$4.29

Pds Biotechnology Corporation Stock (PDSB) Company Profile

Name
Name
Pds Biotechnology Corporation
Name
Phone
800-208-3343
Name
Address
303A COLLEGE ROAD EAST, PRINCETON
Name
Employee
24
Name
Twitter
@pdsbiotech
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
PDSB's Discussions on Twitter

Compare PDSB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PDSB
Pds Biotechnology Corporation
1.18 55.31M 0 -40.56M -35.28M -1.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-01-22 Initiated B. Riley Securities Buy
Jun-28-21 Initiated Cantor Fitzgerald Overweight
Nov-10-20 Upgrade H.C. Wainwright Neutral → Buy
May-27-20 Initiated Alliance Global Partners Buy
Mar-09-20 Initiated Noble Capital Markets Outperform
Oct-24-19 Initiated Chardan Capital Markets Buy
View All

Pds Biotechnology Corporation Stock (PDSB) Latest News

pulisher
Jul 25, 2025

What analysts say about PDS Biotechnology Corporation stockOutstanding trading profits - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What makes PDS Biotechnology Corporation stock price move sharplyReal Time Alert Service - Newser

Jul 25, 2025
pulisher
Jul 25, 2025

Is PDS Biotechnology Corporation stock a good hedge against inflationSuperior risk-adjusted returns - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 23, 2025

PDS Biotechnology Corporation Stock Analysis and ForecastDynamic profit expansion - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

What drives PDS Biotechnology Corporation stock priceFree Stock Movement Tracking - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is PDS Biotechnology Corporation a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How PDS Biotechnology Corporation stock performs during market volatilityHigh Yield Stock Selection - Newser

Jul 22, 2025
pulisher
Jul 15, 2025

Why PDS Biotechnology Corporation stock attracts strong analyst attentionFree Stock Market Knowledge Sharing - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

PDS Biotechnology stock advances as Phase 2 trial meets expansion criteria - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 11, 2025

PDS Biotechnology completes recruitment for stage one of colorectal cancer trial - Yahoo Finance

Jul 11, 2025
pulisher
Jul 10, 2025

PDS Biotechnology Corporation Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

PDS Biotechnology stock rises after trial meets criteria for expansion By Investing.com - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

PDS Biotechnology stock rises after trial meets criteria for expansion - Investing.com Australia

Jul 10, 2025
pulisher
Jul 10, 2025

PDS Biotech's PDS01ADC: A Breakthrough in Cytokine Therapy for Metastatic Colorectal Cancer - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - The Manila Times

Jul 10, 2025
pulisher
Jul 10, 2025

PDS Biotech Achieves Crucial Phase 2 Milestone: Colorectal Cancer Drug Shows Promising Early Results - Stock Titan

Jul 10, 2025
pulisher
Jul 01, 2025

PDS Biotechnology (PDSB) Retains "Buy" Rating with Price Target Unchanged | PDSB Stock News - GuruFocus

Jul 01, 2025
pulisher
Jun 18, 2025

PDSB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com

Jun 18, 2025
pulisher
Jun 17, 2025

Transcript : PDS Biotechnology CorporationSpecial Call - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

PDS Biotechnology holds a conference call - TipRanks

Jun 17, 2025
pulisher
Jun 14, 2025

PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen - Defense World

Jun 14, 2025
pulisher
Jun 14, 2025

HC Wainwright Issues Pessimistic Estimate for PDSB Earnings - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

PDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Millennium Management LLC - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Raises Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

Jun 13, 2025

Pds Biotechnology Corporation Stock (PDSB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):